Product Reports Resources Pricing Login Book a demo

Innovent Biologics

Biotech & Life Sciences · Suzhou Shi, China · Founded 2011 · IPO 2018

Innovent Biologics is a biopharmaceutical company developing and manufacturing monoclonal antibodies

Valuation $16B
Revenue $2.55B
EBITDA $371M
Power Law Decacorn$10B+ valuation tier Thoroughbred$100M+ revenue
Featured in
News Spero secures $105M non-dilutive deal to fund immune-disease drug Jul 14, 2026 News Innovent Biologics secures up to $10.5B Pfizer oncology deal May 29, 2026

Investors

20 investors on Innovent Biologics's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series A 1 investor entered at this stage
F-Prime
Series B+ 19 investors entered at this stage
Legend Capital
Lilly Asia Ventures
Zhonghe Capital
Rock Springs Capital
Ally Bridge Group
SDIC Fund Management
Ping An Capital
Apricot Capital
Temasek
Hillhouse Capital
Taikang Life Insurance
Cormorant Asset Management
Capital Group
Frontline BioVentures
China Life Private Equity Investment
Ping An Group
China Shenzhen New Venture Capital
Eight Roads Ventures
State Development & Investment Corporation (SDIC)

Global footprint

Where Innovent Biologics has talent and traffic

Workforce by country
9 countries with
team presence
🇨🇳 China88.3%
🇺🇸 United States7.8%
🇭🇰 Hong Kong1.5%
🇸🇬 Singapore0.9%
🇬🇧 United Kingdom0.5%
Top 5 of 9 shown
Web traffic by country
20K monthly visits
across markets
🇺🇸 United States37.5%
🇭🇰 Hong Kong17%
🏳️ Korea10.5%
🏳️ Republic of8%
🇯🇵 Japan6.5%
Top 5 markets shown

Talent graph

The shape of Innovent Biologics's talent

Dealroom maps Innovent Biologics's team person by person — pinpointing the standout operators and scoring them across the six dimensions investors underwrite. The counts and shape below are a public preview; the named individuals and exact scores live in the platform.

DimensionScore
AI Talent Score hidden — book a demo
Engineering Score hidden — book a demo
Product Score hidden — book a demo
Go-to-market Score hidden — book a demo
Leadership Score hidden — book a demo
Research Score hidden — book a demo
Book a demo to unlock Innovent Biologics's exact scores

Source: Dealroom Talent Intelligence. Public profiles show counts and the team's shape only — request a demo for the named individuals, per-person seniority and tenure, and team benchmarks vs peers.

Patent intelligence

$84M patent portfolio · 151 active families

Estimated portfolio value
$84M
0.52% of market cap · 138.6× larger than top peer Tubulis ($606k)
151 active patent families
Where Innovent Biologics innovates Anti antibodyAntiendomysial antibodiesBiochemistryBispecific antibodyCancer research

Where Innovent Biologics concentrates vs peers

Each axis is a top-10 topic across Innovent Biologics and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Capital deployed

Innovent Biologics's 2 investments and acquisitions.

Every disclosed deal where Innovent Biologics appeared as a backer or acquirer, 2021–2024. Toggle between venture rounds, M&A, or both. The map below is grouped by the target company's sector — the colored pill on each chip is the round type.

Portfolio analysis

2 deals across Innovent Biologics's capital deployment.

Where the deals concentrate by sector, stage, and decade.

By sectorCount
    By stageCount
      By periodCount

        02 · Portfolio market map

        Innovent Biologics's portfolio, mapped.

        Each chip is one company. Pill colour shows round type — green for Seed, blue for Series A, purple for B/C+, pink for late-stage, amber for M&A. Bigger sectors keep their full list behind “+ N more”.

        Stage
        Period
        2 of 2 deals

        Market sentiment

        What the market is saying about Innovent Biologics

        An AI-synthesized read of the highest-engagement posts about Innovent Biologics on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

        Reading the room on X — pulling top posts and synthesizing themes…

        Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

        See Innovent Biologics on the full Dealroom platform

        Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

        Book a demo Explore company profiles